Rivaroxaban shortage — availability across Europe

Key facts

• As of 5 November 2026, Rivaroxaban has active availability issues in 6 of 10 tracked European registers.
• Registers reporting issues: Austria, Germany, France, Ireland, Italy, Sweden.
• Latest expected-resolution date on file: 2028-12-31.
• Longest-running open report: since 2024-12-27 (23 months, Italy).
• Data source: 6 official medicines-agency registers, refreshed daily.

As of 5 November 2026, 6 of the 10 tracked registers list current availability issues for Rivaroxaban, covering 24 affected product presentations. The longest-running open report was filed in Italy on 2024-12-27 and has now been open for about 23 months. Where agencies state a cause, manufacturing problems lead with 12 of the 15 stated-cause reports, followed by unexpectedly high demand with 3. The furthest expected-resolution date currently on file is 2028-12-31; the earliest is 2026-11-08. Notably, 1 report has already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. Momentum is current, not historical: 17 of the open reports were filed within the last 90 days. The issue spread across registers over time rather than at once: Italy reported first (2024-12-27), with France following roughly 22 months later — a pattern typical of supply problems cascading between national markets. Registers in Germany, Ireland, Italy, Sweden indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Rivaroxaban is coded B01AF01 — a medicine acting on blood and blood-forming organs — so clinically related products appear under “Related medicines” below.

New register reports per month

Full report history (42 register entries)

Every individual register entry for Rivaroxaban in the tracked sources, newest first — including resolved and discontinued reports.

Frequently asked

Is Rivaroxaban currently in shortage in Europe?

Yes. As of 5 November 2026, availability issues are reported in: Austria, Germany, France, Ireland, Italy, Sweden. Availability is national — a shortage in one country does not mean it is short everywhere.

When is the Rivaroxaban shortage expected to end?

Agency prognoses on file range from 2026-11-08 to 2028-12-31. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.

Are there alternatives to Rivaroxaban?

11 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Rivaroxaban availability data come from?

Directly from the official medicines-agency registers that list Rivaroxaban: BASG (Austria), BfArM (Germany), ANSM (France), HPRA (Ireland), AIFA (Italy), Läkemedelsverket (Sweden). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Related medicines (same ATC class)

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Rivaroxaban — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/rivaroxaban/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Rivaroxaban availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/rivaroxaban/">Rivaroxaban shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>